---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-015908"
form_type: "8-K"
ticker: null
cik: "0001840904"
company_name: "ATAI Life Sciences N.V."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:32:38.205973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atai Life Sciences reports Q4 2023 net loss $18.3M, cash $154.2M; BPL-003 Phase 2a shows 45% remission at 3 months

## Summary
- Net loss for Q4 2023 was $18.3M vs $45.0M in Q4 2022; full-year net loss $40.2M vs $152.4M.
- Cash and short-term investments $154.2M as of Dec 31, 2023, down from $273.1M a year ago.
- R&D expenses decreased to $62.2M for FY 2023 from $74.3M; G&A expenses decreased to $63.6M from $70.4M.
- Strategic investment in Beckley Psytech (Jan 2024) added BPL-003 and ELE-101; Phase 2b BPL-003 results expected 2H 2024.
- VLS-01 Phase 1b dosing initiated; COMP360 Phase 3 top-line data expected Q4 2024 and mid-2025.

## SEC filing metadata
- accession: 0001140361-24-015908
- form_type: 8-K
- cik: 0001840904
- company_name: ATAI Life Sciences N.V.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/0001140361-24-015908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/ef20025361_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-015908
- JSON: https://secwatch.observer/filing/0001140361-24-015908.json
- Plain text: https://secwatch.observer/filing/0001140361-24-015908.txt

## Key facts
- Earnings Releases
  ATAI Life Sciences N.V. reported financial results for Q4 and FY 2023.
  - Period: Q4 and FY 2023
  - Result: reported results
  source text: atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/0001140361-24-015908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.